In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF

Chen Yao Su, Ya Po Kuo, Yu Hong Tseng, Ching Hua Su, Thierry Burnouf

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-ß1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.

Original languageEnglish
Pages (from-to)56-61
Number of pages6
JournalOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
Volume108
Issue number1
DOIs
Publication statusPublished - Jul 2009
Externally publishedYes

Fingerprint

Fibrin
Intercellular Signaling Peptides and Proteins
Blood Platelets
Transforming Growth Factors
Somatomedins
Serum
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Polyacrylamide Gel Electrophoresis
Proteins
Membranes
In Vitro Techniques
platelet-derived growth factor AB

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Dentistry(all)
  • Oral Surgery

Cite this

In vitro release of growth factors from platelet-rich fibrin (PRF) : a proposal to optimize the clinical applications of PRF. / Su, Chen Yao; Kuo, Ya Po; Tseng, Yu Hong; Su, Ching Hua; Burnouf, Thierry.

In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, Vol. 108, No. 1, 07.2009, p. 56-61.

Research output: Contribution to journalArticle

@article{e9c5568d718d4a10880b6e7eb48a61f6,
title = "In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF",
abstract = "Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-{\ss}1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.",
author = "Su, {Chen Yao} and Kuo, {Ya Po} and Tseng, {Yu Hong} and Su, {Ching Hua} and Thierry Burnouf",
year = "2009",
month = "7",
doi = "10.1016/j.tripleo.2009.02.004",
language = "English",
volume = "108",
pages = "56--61",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - In vitro release of growth factors from platelet-rich fibrin (PRF)

T2 - a proposal to optimize the clinical applications of PRF

AU - Su, Chen Yao

AU - Kuo, Ya Po

AU - Tseng, Yu Hong

AU - Su, Ching Hua

AU - Burnouf, Thierry

PY - 2009/7

Y1 - 2009/7

N2 - Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-ß1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.

AB - Objective: Determine the release of growth factors (GF) from platelet-rich fibrin (PRF) and supernatant serum to optimize clinical use. Study design: Platelet-derived growth factors-AB (PDGF-AB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor-1 (IGF-1) were quantified in PRF releasate and in the supernatant serum (N = 8) over 300 minutes after clot formation. Protein profiles were determined by SDS-PAGE. Results: Mean quantity of PDGF-AB, TGF-ß1, VEGF, and EGF in PRF releasate increased significantly to about 52, 72, 1, and 3 ng, respectively, whereas mean IGF-1 content remained at 250 ng. GF was also found in serum supernatant. Protein profiles of the releasates and the supernatant serum were similar. Conclusion: The PRF membrane should be used immediately after formation to maximize release of GF to the surgical site. The remaining fluid can be recovered as an additional source of GF for grafting.

UR - http://www.scopus.com/inward/record.url?scp=67649421620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649421620&partnerID=8YFLogxK

U2 - 10.1016/j.tripleo.2009.02.004

DO - 10.1016/j.tripleo.2009.02.004

M3 - Article

C2 - 19451002

AN - SCOPUS:67649421620

VL - 108

SP - 56

EP - 61

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 1

ER -